

August 6, 2020

To whom it may concern

**MSD Animal Health Announcement on U.S. FDA Approval of
BRAVECTO® (fluralaner) Monthly Chews for Dogs**

On July 9, 2020, MSD Animal Health, the veterinary division of Merck & Co., Inc (Head office: Kenilworth, N.J., USA, hereinafter called “MSD”) announced the U.S. Food and Drug Administration (FDA) ’s approval of BRAVECTO® 1-MONTH (fluralaner) Chews for dogs and puppies in 8 weeks of age and older.

BRAVECTO® 1-MONTH is expected to be launched in the United States in the coming months.

Nissan Chemical Corporation (Head office: Chuo-ku, Tokyo; President: KINOSHITA Kojiro) manufactures and supplies the active pharmaceutical ingredient of the BRAVECTO® franchise, fluralaner, to MSD.

BRAVECTO® 1-MONTH is a new addition to the current line-up of BRAVECTO® products. This addition ensures that pet owners can provide flea and tick protection for their dogs and puppies in the early stages of life from 8 weeks of age. They have the option to ease transition to BRAVECTO® Chewable tablets and BRAVECTO® Spot-on with durations for 12 weeks. BRAVECTO® 1-MONTH is available in five doses (45, 100, 200, 400 and 560 mg) per chewable tablet according to the weight (of dogs and puppies).

Along with expansion of the BRAVECTO® franchise, Nissan Chemical Corporation will continue to take advantage of its facilities and know-how in order to meet the demands of MSD and ensure a safe and stable supply of fluralaner.

[Reference] Timeline of the progress of Nissan Chemical’s veterinary medicine business

YEAR	EVENT
2013	First shipment of fluralaner to MSD
2014	BRAVECTO® tablet launched by MSD in EU (Apr.) and U.S. (Jun.)
2015	BRAVECTO® tablet launched from MSD Animal Health K.K. ¹ in Japan
2016	BRAVECTO® spot-on for cats launched by MSD in EU (Jul.), in U.S. (Dec.)
2017	BRAVECTO® spot-on for dogs launched by MSD in Germany and Austria (Jan.)
Mar. 2017	Increased manufacturing capability of fluralaner (multiple manufacturing bases)
Sep. 2017	EXZOLT® launched by MSD in EU
Jul. 2018	BRAVECTO® Plus for Cats launched in EU
Nov. 2019	BRAVECTO® Plus for Cats launched in US
Jul. 2020	BRAVECTO® 1-MONTH approved in US

MSD Animal Health K.K. is a subsidiary of Merck & Co., Inc. in Japan.

About MSD Animal Health

For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.msd-animal-health.com/ or connect with us on LinkedIn and Twitter.

Contact information for inquiries on the above
Nissan Chemical Corporation Corporate Planning Department CSR & Public Relations Office E-mail : csr_pr@nissanchem.co.jp